Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Kern, B; Feurstein, B; Fritz, J; Fabritius, C; Sucher, R; Graziadei, I; Bale, R; Tilg, H; Zoller, H; Newsome, P; Eschertzhuber, S; Margreiter, R; Öfner, D; Schneeberger, S.
High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation.
Eur J Gastroenterol Hepatol. 2019; 31(2):205-210
Doi: 10.1097/MEG.0000000000001270
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Sucher Robert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND AND AIMS: Nonalcoholic steatohepatitis (NASH) is an increasingly prevalent indication for liver transplantation (LT) across the world. The relative outcomes following transplantation are poorly described in this cohort. We aimed to analyze the incidence and outcome of LT for NASH as compared with other indications. PATIENTS AND METHODS: This is a retrospective analysis of 513 patients who underwent deceased-donor, adult LT between 2002 and 2012 as recorded at the Medical University of Innsbruck, Austria. RESULTS: The prevalence of NASH cirrhosis as indication for liver transplantation was 12.7% (65/513). Patient survival in patients with NASH was comparable to other indications, including alcohol-induced liver steatosis (ALD) and hepatitis C virus (HCV) (P=0.208). Patients with NASH were older, had a higher model of end-stage liver disease score and a higher BMI, but patient survival and graft survival were equivalent to other indications. Patients with hepatocellular carcinoma (HCC) as primary indication for liver transplantation showed significantly inferior overall survival as compared with the other indications (P=0.003). Patients with NASH had coexisting HCC in 53.7% of cases, whereas HCC in ALD, HCV and other indications was prevalent in 31.2, 47.7, and 34.5%, respectively (P<0.0001). Patients with NASH had a higher incidence of advanced HCCs (outside the Milan criteria) than patients with ALD, HCV, and other indications (P=0.034). Postoperative complications were significantly higher in the NASH cohort (P=0.048). CONCLUSION: In this single-center LT database analysis, patients with NASH have a higher incidence and a more rapid progression of HCC as well as an increased incidence of postoperative complications. Our findings warrant confirmation by others.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Aged - administration & dosage
- Austria - epidemiology
- Carcinoma, Hepatocellular - diagnosis, epidemiology, surgery
- Databases, Factual - administration & dosage
- Disease Progression - administration & dosage
- Female - administration & dosage
- Graft Survival - administration & dosage
- Humans - administration & dosage
- Incidence - administration & dosage
- Liver Cirrhosis - diagnosis, mortality, surgery
- Liver Neoplasms - diagnosis, mortality, surgery
- Liver Transplantation - adverse effects, mortality
- Male - administration & dosage
- Middle Aged - administration & dosage
- Non-alcoholic Fatty Liver Disease - diagnosis, mortality, surgery
- Postoperative Complications - epidemiology, mortality
- Prevalence - administration & dosage
- Retrospective Studies - administration & dosage
- Risk Factors - administration & dosage
- Time Factors - administration & dosage
- Treatment Outcome - administration & dosage
- Find related publications in this database (Keywords)
- fatty liver disease
- nonalcoholic steatohepatitis
- hepatocellular carcinoma
- liver transplantation
- metabolic syndrome
- outcome